Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Current Obesity Reports
Published in: Current Obesity Reports 4/2015

01-12-2015 | Metabolism (P Trayhurn, Section Editor)

Causes of Vitamin D Deficiency and Effect of Vitamin D Supplementation on Metabolic Complications in Obesity: a Review

Authors: Louise Wamberg, Steen B. Pedersen, Lars Rejnmark, Bjørn Richelsen

Published in: Current Obesity Reports | Issue 4/2015

Login to get access

Abstract

Obese subjects are often characterized by low plasma 25-hydroxy-vitamin D (25OHD) levels. Many explanations for this association have been proposed. Low plasma 25OHD is associated with obesity-related comorbidities such as insulin resistance, type 2 diabetes mellitus, and low-grade inflammation. In this review, we discuss the proposed mechanisms for low 25OHD in obesity and explore the results of recent RCTs on vitamin D (VD) supplementation on obesity and its metabolic complications such as insulin resistance and type 2 diabetes. Although the results from these clinical randomized controlled trials vary, the general picture is that VD treatment of obese individuals does not seem to be an effective treatment of obesity-related metabolic complications.
Literature
1.
Vilarrasa N, Maravall J, Estepa A, et al. Low 25-hydroxyvitamin D concentrations in obese women: their clinical significance and relationship with anthropometric and body composition variables. J Endocrinol Investig. 2007;30(8):653–8.CrossRef
2.
Snijder MB, van Dam RM, Visser M, et al. Adiposity in relation to vitamin D status and parathyroid hormone levels: a population-based study in older men and women. J Clin Endocrinol Metab. 2005;90(7):4119–23.PubMedCrossRef
3.
Parikh SJ, Edelman M, Uwaifo GI, et al. The relationship between obesity and serum 1,25-dihydroxy vitamin D concentrations in healthy adults. J Clin Endocrinol Metab. 2004;89(3):1196–9.PubMedCrossRef
4.
Carlin AM, Rao DS, Meslemani AM, et al. Prevalence of vitamin D depletion among morbidly obese patients seeking gastric bypass surgery. Surg Obes Relat Dis. 2006;2(2):98–103.PubMedCrossRef
5.
Stein EM, Strain G, Sinha N, et al. Vitamin D insufficiency prior to bariatric surgery: risk factors and a pilot treatment study. Clin Endocrinol. 2009;71(2):176–83.CrossRef
6.
Bellia A, Garcovich C, D'Adamo M, et al. Serum 25-hydroxyvitamin D levels are inversely associated with systemic inflammation in severe obese subjects. Intern Emerg Med. 2013;8(1):33–40.PubMedCrossRef
7.
Martins D, Wolf M, Pan D, et al. Prevalence of cardiovascular risk factors and the serum levels of 25-hydroxyvitamin D in the United States: data from the Third National Health and Nutrition Examination Survey. Arch Intern Med. 2007;167(11):1159–65.PubMedCrossRef
8.
Ganji V, Zhang X, Shaikh N, et al. Serum 25-hydroxyvitamin D concentrations are associated with prevalence of metabolic syndrome and various cardiometabolic risk factors in US children and adolescents based on assay-adjusted serum 25-hydroxyvitamin D data from NHANES 2001–2006. Am J Clin Nutr. 2011;94(1):225–33.PubMedCrossRef
9.
Zhang Z, Yuan W, Sun L, et al. 1,25-Dihydroxyvitamin D3 targeting of NF-kappaB suppresses high glucose-induced MCP-1 expression in mesangial cells. Kidney Int. 2007;72(2):193–201.PubMedCrossRef
10.
Cohen-Lahav M, Shany S, Tobvin D, et al. Vitamin D decreases NFkappaB activity by increasing IkappaBalpha levels. Nephrol Dial Transplant. 2006;21(4):889–97.PubMedCrossRef
11.
Eleftheriadis T, Antoniadi G, Liakopoulos V, et al. Paricalcitol reduces basal and lipopolysaccharide-induced (LPS) TNF-α and IL-8 production by human peripheral blood mononuclear cells. Int Urol Nephrol. 2010;42(1):181–5.PubMedCrossRef
12.
Dietary reference intakes for calcium and vitamin D. In: Committee to review dietary reference intakes for calcium and vitamin D. Institute of Medicine; 2011.
13.
Holick MF. Vitamin D: importance in the prevention of cancers, type 1 diabetes, heart disease, and osteoporosis. Am J Clin Nutr. 2004;79(3):362–71.PubMed
14.
15.
16.
Schuster I. Cytochromes P450 are essential players in the vitamin D signaling system. Biochim Biophys Acta. 2011;1814(1):186–99.PubMedCrossRef
17.
Jones G. Pharmacokinetics of vitamin D toxicity. Am J Clin Nutr. 2008;88(2):582S–6.PubMed
18.
Cheng JB, Levine MA, Bell NH, et al. Genetic evidence that the human CYP2R1 enzyme is a key vitamin D 25-hydroxylase. Proc Natl Acad Sci U S A. 2004;101(20):7711–5.PubMedCentralPubMedCrossRef
19.
Shinkyo R, Sakaki T, Kamakura M, et al. Metabolism of vitamin D by human microsomal CYP2R1. Biochem Biophys Res Commun. 2004;324(1):451–7.PubMedCrossRef
20.
Zhu JG, Ochalek JT, Kaufmann M, et al. CYP2R1 is a major, but not exclusive, contributor to 25-hydroxyvitamin D production in vivo. Proc Natl Acad Sci U S A. 2013;110(39):15650–5.PubMedCentralPubMedCrossRef
21.
Gupta RP, Hollis BW, Patel SB, et al. CYP3A4 is a human microsomal vitamin D 25-hydroxylase. J Bone Miner Res. 2004;19(4):680–8.PubMedCrossRef
22.
Usui E, Noshiro M, Ohyama Y, et al. Unique property of liver mitochondrial P450 to catalyze the two physiologically important reactions involved in both cholesterol catabolism and vitamin D activation. FEBS Lett. 1990;274(1–2):175–7.PubMedCrossRef
23.
Aiba I, Yamasaki T, Shinki T, et al. Characterization of rat and human CYP2J enzymes as vitamin D 25-hydroxylases. Steroids. 2006;71(10):849–56.PubMedCrossRef
24.
Zhu J, DeLuca HF. Vitamin D 25-hydroxylase—four decades of searching, are we there yet? Arch Biochem Biophys. 2012;523(1):30–6.PubMedCrossRef
25.
Takeyama K, Kitanaka S, Sato T, et al. 25-Hydroxyvitamin D3 1-alpha-hydroxylase and vitamin D synthesis. Science. 1997;277(5333):1827–30.PubMedCrossRef
26.
Lawson DE, Fraser DR, Kodicek E, et al. Identification of 1,25-dihydroxycholecalciferol, a new kidney hormone controlling calcium metabolism. Nature. 1971;230(5291):228–30.PubMedCrossRef
27.
Zehnder D, Bland R, Williams MC, et al. Extrarenal expression of 25-hydroxyvitamin d(3)-1 alpha-hydroxylase. J Clin Endocrinol Metab. 2001;86(2):888–94.PubMed
28.
Beckman MJ, Tadikonda P, Werner E, et al. Human 25-hydroxyvitamin D3-24-hydroxylase, a multicatalytic enzyme. Biochemistry (Mosc). 1996;35(25):8465–72.CrossRef
29.
Jones G, Prosser DE, Kaufmann M. 25-Hydroxyvitamin D-24-hydroxylase (CYP24A1): its important role in the degradation of vitamin D. Arch Biochem Biophys. 2012;523(1):9–18.PubMedCrossRef
30.
DeLuca HF. Overview of general physiologic features and functions of vitamin D. Am J Clin Nutr. 2004;80(6 Suppl):1689S–96.PubMed
31.
Haussler MR, Jurutka PW, Mizwicki M, et al. Vitamin D receptor (VDR)-mediated actions of 1alpha,25(OH)(2)vitamin D(3): genomic and non-genomic mechanisms. Best Pract Res Clin Endocrinol Metab. 2011;25(4):543–59.PubMedCrossRef
32.
Wang Y, Zhu J, DeLuca HF. Where is the vitamin D receptor? Arch Biochem Biophys. 2012;523(1):123–33.PubMedCrossRef
33.
34.
Ching S, Kashinkunti S, Niehaus MD, et al. Mammary adipocytes bioactivate 25-hydroxyvitamin D3 and signal via vitamin D3 receptor, modulating mammary epithelial cell growth. J Cell Biochem. 2011;112(11):3393–405.PubMedCentralPubMedCrossRef
35.
Mawer EB, Backhouse J, Holman CA, et al. The distribution and storage of vitamin D and its metabolites in human tissues. Clin Sci. 1972;43(3):413–31.PubMedCrossRef
36.
Rosenstreich SJ, Rich C, Volwiler W. Deposition in and release of vitamin D3 from body fat: evidence for a storage site in the rat. J Clin Invest. 1971;50(3):679–87.PubMedCentralPubMedCrossRef
37.
Heaney RP, Horst RL, Cullen DM, et al. Vitamin D3 distribution and status in the body. J Am Coll Nutr. 2009;28(3):252–6.PubMedCrossRef
38.
39.
Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2011;96(7):1911–30.PubMedCrossRef
40.
Pereira-Santos M, Costa PR, Assis AM, et al. Obesity and vitamin D deficiency: a systematic review and meta-analysis. Obes Rev. 2015;16(4):341–9.PubMedCrossRef
41.
Fornari R, Francomano D, Greco EA, et al. Lean mass in obese adult subjects correlates with higher levels of vitamin D, insulin sensitivity and lower inflammation. J Endocrinol Investig 2014, DOI: 10.​1007/​s40618-014-0189-z: 1–6.
42.
Caron-Jobin M, Morisset AS, Tremblay A, et al. Elevated serum 25(OH)D concentrations, vitamin D, and calcium intakes are associated with reduced adipocyte size in women. Obesity. 2011;19(7):1335–41.PubMedCrossRef
43.
44.
Kremer R, Campbell PP, Reinhardt T, et al. Vitamin D status and its relationship to body fat, final height, and peak bone mass in young women. J Clin Endocrinol Metab. 2009;94(1):67–73.PubMedCentralPubMedCrossRef
45.
Young KA, Engelman CD, Langefeld CD, et al. Association of plasma vitamin D levels with adiposity in Hispanic and African Americans. J Clin Endocrinol Metab. 2009;94(9):3306–13.PubMedCentralPubMedCrossRef
46.•
Vimaleswaran KS, Berry DJ, Lu C, et al. Causal relationship between obesity and vitamin D status: bi-directional Mendelian randomization analysis of multiple cohorts. PLoS Med. 2013;10(2):e1001383. Demonstrates genetic evidence of a causal association between obesity and vitamin D deficiency.PubMedCentralPubMedCrossRef
47.
Kull M, Kallikorm R, Lember M. Body mass index determines sunbathing habits: implications on vitamin D levels. Intern Med J. 2009;39(4):256–8.PubMedCrossRef
48.
49.
Bell NH, Shaw S, Turner RT. Evidence that 1,25-dihydroxyvitamin-D3 inhibits the hepatic production of 25-hydroxyvitamin-D in man. Calcif Tissue Int. 1984;36(4):510.
50.
Targher G, Bertolini L, Scala L, et al. Associations between serum 25-hydroxyvitamin D3 concentrations and liver histology in patients with non-alcoholic fatty liver disease. Nutr Metab Cardiovasc Dis. 2007;17(7):517–24.PubMedCrossRef
51.
52.
Wortsman J, Matsuoka LY, Chen TC, et al. Decreased bioavailability of vitamin D in obesity. Am J Clin Nutr. 2000;72(3):690–3.PubMed
53.
Wamberg L, Christiansen T, Paulsen SK, et al. Expression of vitamin D-metabolizing enzymes in human adipose tissue—the effect of obesity and diet-induced weight loss. Int J Obes. 2013;37(5):651–7.CrossRef
54.•
Drincic AT, Armas LAG, Van Diest EE. Volumetric dilution, rather than sequestration best explains the low vitamin D status of obesity. Obesity. 2012;20:1444–8. Demonstrates that the differences in vitamin D status between lean and obese subjects can be explained by differences in body size.PubMedCrossRef
55.
Drincic A, Fuller E, Heaney RP, et al. 25-Hydroxyvitamin D response to graded vitamin D(3) supplementation among obese adults. J Clin Endocrinol Metab. 2013;98(12):4845–51.PubMedCrossRef
56.
Reinehr T, de SG, Alexy U, et al. Vitamin D status and parathyroid hormone in obese children before and after weight loss. Eur J Endocrinol. 2007;157(2):225–32.PubMedCrossRef
57.
Tzotzas T, Papadopoulou FG, Tziomalos K, et al. Rising serum 25-hydroxy-vitamin D levels after weight loss in obese women correlate with improvement in insulin resistance. J Clin Endocrinol Metab. 2010;95(9):4251–7.PubMedCrossRef
58.
Villareal DT, Shah K, Banks MR, et al. Effect of weight loss and exercise therapy on bone metabolism and mass in obese older adults: a one-year randomized controlled trial. J Clin Endocrinol Metab. 2008;93(6):2181–7.PubMedCentralPubMedCrossRef
59.
Rock CL, Emond JA, Flatt SW, et al. Weight loss is associated with increased serum 25-hydroxyvitamin D in overweight or obese women. Obesity. 2012;20(11):2296–301.PubMedCrossRef
60.
61.
Aasheim ET, Johnson LK, Hofso D, et al. Vitamin status after gastric bypass and lifestyle intervention: a comparative prospective study. Surg Obes Relat Dis. 2012;8(2):169–75.PubMedCrossRef
62.
Lin E, Armstrong-Moore D, Liang Z, et al. Contribution of adipose tissue to plasma 25-hydroxyvitamin D concentrations during weight loss following gastric bypass surgery. Obesity. 2011;19(3):588–94.PubMedCentralPubMedCrossRef
63.
Tsiftsis D, Mylonas P, Mead N, et al. Bone mass decreases in morbidly obese women after long limb-biliopancreatic diversion and marked weight loss without secondary hyperparathyroidism. A physiological adaptation to weight loss? Obes Surg. 2009;19(11):1497–503.PubMedCrossRef
64.
Sinha N, Shieh A, Stein EM, et al. Increased PTH and 1.25(OH)2D levels associated with increased markers of bone turnover following bariatric surgery. Obesity. 2011;19(12):2388–93.PubMedCentralPubMedCrossRef
65.
Ruiz-Tovar J, Oller I, Tomas A, et al. Mid-term effects of sleeve gastrectomy on calcium metabolism parameters, vitamin D and parathormone (PTH) in morbid obese women. Obes Surg. 2011;22(5):797–801.CrossRef
66.
Aasheim ET, Bjorkman S, Sovik TT, et al. Vitamin status after bariatric surgery: a randomized study of gastric bypass and duodenal switch. Am J Clin Nutr. 2009;90(1):15–22.PubMedCrossRef
67.
Pramyothin P, Biancuzzo RM, Lu Z, et al. Vitamin D in adipose tissue and serum 25-hydroxyvitamin D after Roux-en-Y gastric bypass. Obesity. 2011;19(11):2228–34.PubMedCrossRef
68.
Kamei Y, Kawada T, Kazuki R, et al. Vitamin D receptor gene expression is up-regulated by 1, 25-dihydroxyvitamin D3 in 3T3-L1 preadipocytes. Biochem Biophys Res Commun. 1993;193(3):948–55.PubMedCrossRef
69.
Querfeld U, Hoffmann MM, Klaus G, et al. Antagonistic effects of vitamin D and parathyroid hormone on lipoprotein lipase in cultured adipocytes. J Am Soc Nephrol. 1999;10(10):2158–64.PubMed
70.
Fu M, Sun T, Bookout AL, et al. A nuclear receptor atlas: 3T3-L1 adipogenesis. Mol Endocrinol. 2005;19(10):2437–50.PubMedCrossRef
71.
Bellows CG, Wang YH, Heersche JN, et al. 1,25-dihydroxyvitamin D3 stimulates adipocyte differentiation in cultures of fetal rat calvaria cells: comparison with the effects of dexamethasone. Endocrinology. 1994;134(5):2221–9.PubMed
72.
Dace A, Martin-el Yazidi C, Bonne J, et al. Calcitriol is a positive effector of adipose differentiation in the OB 17 cell line: relationship with the adipogenic action of triiodothyronine. Biochem Biophys Res Commun. 1997;232(3):771–6.PubMedCrossRef
73.
Atmani H, Chappard D, Basle MF. Proliferation and differentiation of osteoblasts and adipocytes in rat bone marrow stromal cell cultures: effects of dexamethasone and calcitriol. J Cell Biochem. 2003;89(2):364–72.PubMedCrossRef
74.
Kong J, Li YC. Molecular mechanism of 1,25-dihydroxyvitamin D3 inhibition of adipogenesis in 3T3-L1 cells. Am J Physiol Endocrinol Metab. 2006;290(5):E916–24.PubMedCrossRef
75.
Blumberg JM, Tzameli I, Astapova I, et al. Complex role of the vitamin D receptor and its ligand in adipogenesis in 3T3-L1 cells. J Biol Chem. 2006;281(16):11205–13.PubMedCrossRef
76.
Lee H, Bae S, Yoon Y. Anti-adipogenic effects of 1,25-dihydroxyvitamin D3 are mediated by the maintenance of the wingless-type MMTV integration site/beta-catenin pathway. Int J Mol Med. 2012;30(5):1219–24.PubMed
77.
Cianferotti L, Demay MB. VDR-mediated inhibition of DKK1 and SFRP2 suppresses adipogenic differentiation of murine bone marrow stromal cells. J Cell Biochem. 2007;101(1):80–8.PubMedCrossRef
78.
Mai XM, Chen Y, Camargo Jr CA, et al. Cross-sectional and prospective cohort study of serum 25-hydroxyvitamin D level and obesity in adults: the HUNT study. Am J Epidemiol. 2012;175(10):1029–36.PubMedCrossRef
79.
LeBlanc ES, Rizzo JH, Pedula KL, et al. Associations between 25-hydroxyvitamin D and weight gain in elderly women. J Womens Health (Larchmt). 2012;21(10):1066–73.PubMedCentralCrossRef
80.
Zhu W, Cai D, Wang Y, et al. Calcium plus vitamin D3 supplementation facilitated fat loss in overweight and obese college students with very-low calcium consumption: a randomized controlled trial. Nutr J 2013; 12(8).
81.
Rosenblum JL, Castro M, Moore CE, et al. Calcium and vitamin D supplementation is associated with decreased abdominal visceral adipose tissue in overweight and obese adults. Am J Clin Nutr. 2012;95(1):101–8.PubMedCentralPubMedCrossRef
82.
Sneve M, Figenschau Y, Jorde R. Supplementation with cholecalciferol does not result in weight reduction in overweight and obese subjects. Eur J Endocrinol. 2008;159(6):675–84.PubMedCrossRef
83.
Wamberg L, Kampmann U, Stodkilde-Jorgensen H, et al. Effects of vitamin D supplementation on body fat accumulation, inflammation, and metabolic risk factors in obese adults with low vitamin D levels—results from a randomized trial. Eur J Intern Med. 2013;24(7):644–9.PubMedCrossRef
84.
Salehpour A, Shidfar F, Hosseinpanah F, et al. Does vitamin D3 supplementation improve glucose homeostasis in overweight or obese women? A double-blind, randomized, placebo-controlled clinical trial. Diabet Med. 2013;30(12):1477–81.PubMedCrossRef
85.
Mason C, Xiao L, Imayama I, et al. Vitamin D3 supplementation during weight loss: a double-blind randomized controlled trial. Am J Clin Nutr. 2014;99(5):1015–25.PubMedCentralPubMedCrossRef
86.
Shab-Bidar S, Neyestani TR, Djazayery A, et al. Regular consumption of vitamin D-fortified yogurt drink (Doogh) improved endothelial biomarkers in subjects with type 2 diabetes: a randomized double-blind clinical trial. BMC Med 2011; 9(125).
87.
Kampmann U, Mosekilde L, Juhl C, et al. Effects of 12 weeks high dose vitamin D3 treatment on insulin sensitivity, beta cell function, and metabolic markers in patients with type 2 diabetes and vitamin D insufficiency—a double-blind, randomized, placebo-controlled trial. Metabolism. 2014;63(9):1115–24.PubMedCrossRef
88.
89.
Xu H, Barnes GT, Yang Q, et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest. 2003;112(12):1821–30.PubMedCentralPubMedCrossRef
90.
Berg AH, Scherer PE. Adipose tissue, inflammation, and cardiovascular disease. Circ Res. 2005;96(9):939–49.PubMedCrossRef
91.
Lorente-Cebrian S, Eriksson A, Dunlop T, et al. Differential effects of 1alpha,25-dihydroxycholecalciferol on MCP-1 and adiponectin production in human white adipocytes. Eur J Nutr. 2012;51(3):335–42.PubMedCrossRef
92.
Wamberg L, Cullberg KB, Rejnmark L, et al. Investigations of the anti-inflammatory effects of vitamin D in adipose tissue: results from an in vitro study and a randomized controlled trial. Horm Metab Res. 2013;45(6):456–62.PubMedCrossRef
93.
Pittas AG, Harris SS, Stark PC, et al. The effects of calcium and vitamin D supplementation on blood glucose and markers of inflammation in nondiabetic adults. Diabetes Care. 2007;30(4):980–6.PubMedCrossRef
94.
Zittermann A, Frisch S, Berthold HK, et al. Vitamin D supplementation enhances the beneficial effects of weight loss on cardiovascular disease risk markers. Am J Clin Nutr. 2009;89(5):1321–7.PubMedCrossRef
95.
Schleithoff SS, Zittermann A, Tenderich G, et al. Vitamin D supplementation improves cytokine profiles in patients with congestive heart failure: a double-blind, randomized, placebo-controlled trial. Am J Clin Nutr. 2006;83(4):754–9.PubMed
96.
Jorde R, Sneve M, Torjesen PA, et al. No effect of supplementation with cholecalciferol on cytokines and markers of inflammation in overweight and obese subjects. Cytokine. 2010;50(2):175–80.PubMedCrossRef
97.
Chen N, Wan Z, Han SF, et al. Effect of vitamin D supplementation on the level of circulating high-sensitivity C-reactive protein: a meta-analysis of randomized controlled trials. Nutrients. 2014;6(6):2206–16.PubMedCentralPubMedCrossRef
98.
Shab-Bidar S, Neyestani TR, Djazayery A, et al. Improvement of vitamin D status resulted in amelioration of biomarkers of systemic inflammation in the subjects with type 2 diabetes. Diabetes Metab Res Rev. 2012;28(5):424–30.PubMedCrossRef
99.
Norman AW, Frankel JB, Heldt AM, et al. Vitamin D deficiency inhibits pancreatic secretion of insulin. Science. 1980;209(4458):823–5.PubMedCrossRef
100.
Cade C, Norman AW. Vitamin D3 improves impaired glucose tolerance and insulin secretion in the vitamin D-deficient rat in vivo. Endocrinology. 1986;119(1):84–90.PubMedCrossRef
101.
Calle C, Maestro B, Garcia-Arencibia M. Genomic actions of 1,25-dihydroxyvitamin D3 on insulin receptor gene expression, insulin receptor number and insulin activity in the kidney, liver and adipose tissue of streptozotocin-induced diabetic rats. BMC Mol Biol 2008; 9(65).
102.
Tai K, Need AG, Horowitz M, et al. Vitamin D, glucose, insulin, and insulin sensitivity. Nutrition. 2008;24(3):279–85.PubMedCrossRef
103.
Need AG, O'Loughlin PD, Horowitz M, et al. Relationship between fasting serum glucose, age, body mass index and serum 25 hydroxyvitamin D in postmenopausal women. Clin Endocrinol. 2005;62(6):738–41.CrossRef
104.
Baynes KC, Boucher BJ, Feskens EJ, et al. Vitamin D, glucose tolerance and insulinaemia in elderly men. Diabetologia. 1997;40(3):344–7.PubMedCrossRef
105.
Chiu KC, Chu A, Go VLW, et al. Hypovitaminosis D is associated with insulin resistance and beta cell dysfunction. Am J Clin Nutr. 2004;79(5):820–5.PubMed
106.
Grimnes G, Emaus N, Joakimsen RM, et al. Baseline serum 25-hydroxyvitamin D concentrations in the Tromso Study 1994–95 and risk of developing type 2 diabetes mellitus during 11 years of follow-up. Diabet Med. 2010;27(10):1107–15.PubMedCrossRef
107.
Thorand B, Zierer A, Huth C, et al. Effect of serum 25-hydroxyvitamin D on risk for type 2 diabetes may be partially mediated by subclinical inflammation: results from the MONICA/KORA Augsburg study. Diabetes Care. 2011;34(10):2320–2.PubMedCentralPubMedCrossRef
108.
Jorde R, Figenschau Y. Supplementation with cholecalciferol does not improve glycaemic control in diabetic subjects with normal serum 25-hydroxyvitamin D levels. Eur J Nutr. 2009;48(6):349–54.PubMedCrossRef
109.
Kumar S, Davies M, Zakaria Y, et al. Improvement in glucose tolerance and beta-cell function in a patient with vitamin D deficiency during treatment with vitamin D. Postgrad Med J. 1994;70(824):440–3.PubMedCentralPubMedCrossRef
110.
Gedik O, Akalin S. Effects of vitamin D deficiency and repletion on insulin and glucagon secretion in man. Diabetologia. 1986;29(3):142–5.PubMedCrossRef
111.
Nagpal J, Pande JN, Bhartia A. A double-blind, randomized, placebo-controlled trial of the short-term effect of vitamin D3 supplementation on insulin sensitivity in apparently healthy, middle-aged, centrally obese men. Diabet Med. 2009;26(1):19–27.PubMedCrossRef
112.
Tai K, Need AG, Horowitz M, et al. Glucose tolerance and vitamin D: effects of treating vitamin D deficiency. Nutrition. 2008;24(10):950–6.PubMedCrossRef
113.
von Hurst PR, Stonehouse W, Coad J. Vitamin D supplementation reduces insulin resistance in South Asian women living in New Zealand who are insulin resistant and vitamin D deficient—a randomised, placebo-controlled trial. Br J Nutr. 2010;103(4):549–55.CrossRef
114.
Harris SS, Pittas AG, Palermo NJ. A randomized, placebo-controlled trial of vitamin D supplementation to improve glycaemia in overweight and obese African Americans. Diabetes Obes Metab. 2012;14(9):789–94.PubMedCrossRef
115.
Breslavsky A, Frand J, Matas Z, et al. Effect of high doses of vitamin D on arterial properties, adiponectin, leptin and glucose homeostasis in type 2 diabetic patients. Clin Nutr. 2013;32(6):970–5.PubMedCrossRef
116.
Kendrick J, Targher G, Smits G, et al. 25-Hydroxyvitamin D deficiency is independently associated with cardiovascular disease in the Third National Health and Nutrition Examination Survey. Atherosclerosis. 2009;205(1):255–60.PubMedCrossRef
117.
118.
Forman JP, Curhan GC, Taylor EN. Plasma 25-hydroxyvitamin D levels and risk of incident hypertension among young women. Hypertension. 2008;52(5):828–32.PubMedCentralPubMedCrossRef
119.
Wang L, Manson JE, Buring JE, et al. Dietary intake of dairy products, calcium, and vitamin D and the risk of hypertension in middle-aged and older women. Hypertension. 2008;51(4):1073–9.PubMedCrossRef
120.
Ertek S, Akgul E, Cicero AF, et al. 25-Hydroxy vitamin D levels and endothelial vasodilator function in normotensive women. Arch Med Sci. 2012;8(1):47–52.PubMedCentralPubMedCrossRef
121.
122.
Lind L, Wengle B, Wide L, et al. Reduction of blood pressure during long-term treatment with active vitamin D (alphacalcidol) is dependent on plasma renin activity and calcium status. A double-blind, placebo-controlled study. Am J Hypertens. 1989;2(1):20–5.PubMed
123.
Pfeifer M, Begerow B, Minne HW, et al. Effects of a short-term vitamin D(3) and calcium supplementation on blood pressure and parathyroid hormone levels in elderly women. J Clin Endocrinol Metab. 2001;86(4):1633–7.PubMed
124.
Witham MD, Dove FJ, Dryburgh M, et al. The effect of different doses of vitamin D(3) on markers of vascular health in patients with type 2 diabetes: a randomised controlled trial. Diabetologia. 2010;53(10):2112–9.PubMedCrossRef
125.
Vimaleswaran KS, Cavadino A, Berry DJ, et al. Association of vitamin D status with arterial blood pressure and hypertension risk: a Mendelian randomisation study. Lancet Diabetes Endocrinol. 2014;2(9):719–29.PubMedCentralPubMedCrossRef
126.
Beveridge LA, Struthers AD, Khan F, et al. Effect of vitamin D supplementation on blood pressure: a systematic review and meta-analysis incorporating individual patient data. JAMA Intern Med. 2015;175(5):745–54.PubMedCrossRef
127.
Jorde R, Grimnes G. Vitamin D and metabolic health with special reference to the effect of vitamin D on serum lipids. Prog Lipid Res. 2011;50(4):303–12.PubMedCrossRef
128.
Cho HJ, Kang HC, Choi SA, et al. The possible role of Ca2+ on the activation of microsomal triglyceride transfer protein in rat hepatocytes. Biol Pharm Bull. 2005;28(8):1418–23.PubMedCrossRef
129.
Zemel MB, Shi H, Greer B, et al. Regulation of adiposity by dietary calcium. FASEB J. 2000;14(9):1132–8.PubMed
130.
Piccolo BD, Dolnikowski G, Seyoum E, et al. Association between subcutaneous white adipose tissue and serum 25-hydroxyvitamin D in overweight and obese adults. Nutrients. 2013;5(9):3352–66.PubMedCentralPubMedCrossRef
131.
Seida JC, Mitri J, Colmers IN, et al. Clinical review: effect of vitamin D3 supplementation on improving glucose homeostasis and preventing diabetes: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2014;99(10):3551–60.PubMedCentralPubMedCrossRef
132.
Beilfuss J, Berg V, Sneve M, et al. Effects of a 1-year supplementation with cholecalciferol on interleukin-6, tumor necrosis factor-alpha and insulin resistance in overweight and obese subjects. Cytokine. 2012;60(3):870–4.PubMedCrossRef
133.
Neyestani TR, Nikooyeh B, Alavi-Majd H, et al. Improvement of vitamin D status via daily intake of fortified yogurt drink either with or without extra calcium ameliorates systemic inflammatory biomarkers, including adipokines, in the subjects with type 2 diabetes. J Clin Endocrinol Metab. 2012;97(6):2005–11.PubMedCrossRef
134.
Chandler PD, Scott JB, Drake BF, et al. Impact of vitamin D supplementation on inflammatory markers in African Americans: results of a four-arm, randomized, placebo-controlled trial. Cancer Prev Res (Phila). 2014;7(2):218–25.CrossRef
135.
Duggan C, Tapsoba JD, Mason C, et al. Effect of vitamin D3 supplementation in combination with weight loss on inflammatory biomarkers in postmenopausal women: a randomized controlled trial. Cancer Prev Res (Phila). 2015. doi:10.​1158/​1940-6207.​CAPR-14-0449:​.
136.
Wongwiwatthananukit S, Sansanayudh N, Phetkrajaysang N, et al. Effects of vitamin D(2) supplementation on insulin sensitivity and metabolic parameters in metabolic syndrome patients. J Endocrinol Investig. 2013;36(8):558–63.
Metadata
Title
Causes of Vitamin D Deficiency and Effect of Vitamin D Supplementation on Metabolic Complications in Obesity: a Review
Authors
Louise Wamberg
Steen B. Pedersen
Lars Rejnmark
Bjørn Richelsen
Publication date
01-12-2015
Publisher
Springer US
Published in
Current Obesity Reports / Issue 4/2015
Electronic ISSN: 2162-4968
DOI
https://doi.org/10.1007/s13679-015-0176-5

Other articles of this Issue 4/2015

Current Obesity Reports 4/2015 Go to the issue

Economy and Environment (I Janssen, Section Editor)

Playability: Built and Social Environment Features That Promote Physical Activity Within Children

Metabolism (P Trayhurn, Section Editor)

The Influence of Bariatric Surgery on Serum Bile Acids in Humans and Potential Metabolic and Hormonal Implications: a Systematic Review

Economy and Environment (I Janssen, Section Editor)

Disability Discrimination and Obesity: The Big Questions?

Economy and Environment (I Janssen, Section Editor)

Beyond Physical Activity: The Importance of Play and Nature-Based Play Spaces for Children’s Health and Development

Metabolism (P Trayhurn, Section Editor)

Recent Progress in the Understanding of Obesity: Contributions of Genome-Wide Association Studies

Metabolism (P Trayhurn, Section Editor)

Gut Microbiota Dysbiosis in Obesity-Linked Metabolic Diseases and Prebiotic Potential of Polyphenol-Rich Extracts

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits